CARM vs MGTX vs FATE vs JPM

For growth investors, MeiraGTx Holdings plc (MGTX) is the stronger pick with 144.

6% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 2x trailing P/E (14. 6x forward), making it the more compelling value choice. Analysts rate MeiraGTx Holdings plc (MGTX) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +135. 5%, compared to -99. 6% for Carisma Therapeutics, Inc. (CARM). Over 10 years, the gap is even starker: JPM returned +481. 2% versus CARM's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Carisma Therapeutics, Inc.

(CARM) is the lower-risk stock at -0. 80β versus MeiraGTx Holdings plc's 1. 88β — meaning MGTX is approximately -335% more volatile than CARM relative to the S&P 500. On balance sheet safety, Fate Therapeutics, Inc. (FATE) carries a lower debt/equity ratio of 38% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), MeiraGTx Holdings plc (MGTX) is pulling ahead at 144.

6% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Carisma Therapeutics, Inc. grew EPS 43. 6% year-over-year, compared to 1. 5% for JPMorgan Chase & Co.. Over a 3-year CAGR, MGTX leads at 72. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -22. 2% for FATE. At the gross margin level — before operating expenses — MGTX leads at 94. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for FATE: 163.

2% to $5. 50.

In this comparison, JPM (1.

8% yield) pays a dividend. CARM, MGTX, FATE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Carisma Therapeutics, Inc.

(CARM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 80)). MeiraGTx Holdings plc (MGTX) carries a higher beta of 1. 88 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CARM: -99. 1%, MGTX: -24. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CARM (Healthcare) and MGTX (Healthcare) and FATE (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CARM is a small-cap high-growth stock; MGTX is a small-cap high-growth stock; FATE is a small-cap quality compounder stock; JPM is a large-cap deep-value stock. JPM pays a dividend while CARM, MGTX, FATE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.